News Detail

BioQ Pharma Receives Australian Regulatory Approval for Propofol Product – Propofusor 1%

Jun 28, 2019

SAN FRANCISCO, June 28, 2019: BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Propofusor product containing 1% propofol in a single-use dispensing system. Uses of the Propofusor include the induction and maintenance of general anesthesia, sedation of mechanically ventilated adults in intensive care, and conscious sedation during diagnostic and surgical procedures. With an estimated 2.5 million surgical and 1.2 million gastrointestinal procedures annually, the market opportunity for anesthesia therapies in Australia is approximately A$500 million.

Using the Company’s patented invenious™ technology, the Propofusor is a programmable, ready-to-use, single use infusion pharmaceutical product, which is pre-filled at the point of manufacture with 1% propofol, a hypnotic amnestic agent and the world’s most widely used surgical sedation drug. The self-contained system provides the ability to titrate dosage, as well as bolus capabilities.

Josh Kriesel, President and CEO of BioQ Pharma, commented, “We are looking forward to launching the Propofusor in Australia in collaboration with Stada, our Australian commercial partner, in the near-term. There is a need for convenient, ready-to-use anesthetic products in hospitals, outpatient centers and clinics that could help avoid dosing errors and breaches in sterility.”

About BioQ Pharma

BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals using its patented invenious™ technology. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Stada, Cipla, Lee's Pharm, Lunatus, Lenis, POA Pharma, Sophos Biotech, Xantis Pharma, Taiba Pharmacy, Pharmamart, and West Pharmaceutical Services.